Welcome to the Journal
ISSN: 2041-6792 | *Journal Impact Factor: 2.75 | NLM ID: 101554582 Journal Membership services
Clinical Investigation (OACLI) (2041-6792) plays significant role in the diagnosis, therapy and cure of diseases apart from new drug development and delivery. The Clinical Investigation Journal offers an Open Access platform to the scholars, amateurs, clinical practitioners and students that are keen in contributing their findings in this field.
Clinical Investigation (OACLI) caters to the clinical drug development and methodology, facilitating rapid publication of research outcome on new drug data from human studies. The journal includes topics like safety and effectiveness of medications, devices, diagnostic products and treatment regimens intended for human use. Also the journal publishes expert analysis of ongoing Phase I–IV trials and perspectives on how to run future trials.
The journal offers thoroughly reviewed original research as research articles, review articles, Clinical Trial Protocols, Clinical Trial Perspectives, Clinical Trial Outcomes, Clinical Trial Reports, Clinical Trial Methodologies, Clinical Trial phase I-IV findings, Commentaries on Clinical trials, case studies, commentaries, Short Communication, and Letters to the Editors in the areas not limited to Regulations and guidelines on drug development and delivery, legal and ethical issues of clinical trials, issues of testing of novel drugs, new medical procedure, new medical devices etc.
Submit your manuscripts online at Editorial Tracking online submission: https://www.scholarscentral.org/submissions/clinical-investigation.html
Contact Editorial Office or send attachment of manuscript at any of the following mail id: [email protected]
Recently Published Articles
Research Article p. 117-121
Failure to replicate a previously reported GWAS association between KCNJ1 gene and co-amoxiclav-induced liver injury
Author(s): Mohammad A. Alshabeeb
Background: Co-amoxiclav is associated with Drug-Induced Liver Injury (DILI). HLA genotype is an important predictor of DILI susceptibility but it is likely that non-HLA risk factors also co..
Editorial
Editorial note for clinical investigation
Author(s): Sreejata Chatterjee
It feels immense pleasure to share that the Journal of Clinical Investigation(OACLI) issue release frequency has been changed to quarterly (4 issues per year). The first issue of the journal..
Editorial
Acknowledgement to Reviewers of Clinical Investigation Journal
Author(s): Sinerik Ayrapetyan
On behalf of the editors of the Clinical Investigation Journal, I would like to express my sincere gratitude to the reviewers for assessing manuscripts. The editors greatly appreciate the co..
Brief Report
A comparative clinical trial to assess a standardized escalation dose strategy of interleukin-1 blockade in Kawasaki disease: The ANACOMP trial
Author(s): Isabelle Kone-Paut*, Artemis Toumazi, Aurelie Bourmaud
Background: Based on the auto-inflammatory pattern of Kawasaki Disease (KD), the most frequent and heart threatening vasculitis in children before five years, we hypothesize that anti-IL-1 b..
